media – Page 25 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Progress has been made in the construction of HSV-1 oncolytic virus where Wuhan virus is located

Recently, Hu Zhihong, Wang Manli, Luo Minhua and Zeng Wenbo from the Wuhan Institute of Virology, Chinese Academy of Sciences, jointly published a research paper entitled “Efficient Strategy for Synthesizing Vector Free and Oncolytic Herpes Simplex Type 1 Viruses” on the international academic journal ACS Synthetic Biology. This research carried out the construction and optimization of an artificial synthesis platform based on type I herpes simplex virus type F, and used this platform to transform oncolytic viruses. Type I herpes simplex virus (HSV-1) has important application prospects as an oncolytic virus in cancer treatment. In this study, the research team developed a new method for efficient synthesis and rescue of HSV-1 virus. Unlike traditional methods of synthesizing complete genomes containing vector sequences in vitro and transfecting them into mammalian cells to rescue viruses, the research team synthesized HSV-1 genome fragments containing homologous arms through transformation related homologous recombination (TAR) in ...
- Source: drugdu
- 62
- October 16, 2024
Pfizer’s innovative drug HYMPAVZI ™ Mataximab hncq has been approved by the FDA for the treatment of hemophilia A and hemophilia B

The approval of HYMPAVZI is based on the results of a phase III trial study, which showed that compared with factor based prophylaxis and on-demand treatment, the drug can significantly reduce bleeding rates in eligible hemophilia A and hemophilia B patients without inhibitors. HYMPAVZI is the first weekly subcutaneous injection regimen provided in the United States for eligible hemophilia B patients. At the same time, it is also the first regular treatment provided to eligible hemophilia A and hemophilia B patients through pre filled injection pens or syringes. Recently, Pfizer’s innovative drug HYMPAVZI ™ Mataximab hncq has been approved by the US Food and Drug Administration (FDA) for the regular treatment of hemophilia A (congenital factor VIII deficiency) or hemophilia B (congenital factor IX deficiency) patients over 12 years old without coagulation factor inhibitors, in order to reduce bleeding episodes. HYMPAVZI is the first and only approved anti tissue factor ...
- Source: drugdu
- 65
- October 16, 2024
The “wolf” is really here, and the elimination of zombie approvals has begun

While the industry is still waiting to see whether the “zombie” approvals will really be eliminated, the new regulations of the National Medical Products Administration have provided a policy basis for the elimination of “zombie” approvals-On October 12, 2024, the National Medical Products Administration issued a notice on the application procedures and application materials requirements for re-registration of domestically produced drugs (No. 38 of 2024), which will be implemented from January 1, 2025. According to the new regulations on re-registration, three types of approvals will face the risk of delisting. The first type of risky products: “zombie” approvals, especially those with missing production scope and production address The “zombie” approvals mentioned above are very likely to be delisted: The “Application Procedures for Re-registration of Domestically Produced Drugs” clearly requires “strengthening the management of drugs that have not been produced on a commercial scale during the period from the approval of ...
- Source: drugdu
- 60
- October 16, 2024
Important document! Secondary bargaining is “stopped”

Regarding the scope of the special rectification of “secondary bargaining” defined in the notice, the author consulted the relevant responsible personnel of the Finance Department of the Hunan Provincial Health Commission, and received the reply: This “secondary bargaining” rectification focuses on the behavior of public hospitals not settling according to the agreed purchase and sale prices in order to obtain irregular rebates. At present, most hospitals in Hunan Province are involved in “secondary bargaining” rebates to varying degrees and in different forms, such as bearing the cost of drug consumption fund recovery and deducting penalties for excessive drug use as the name and method of rebates. The rebate income from “secondary bargaining” is used by hospitals to supplement related operating costs. This time, the Hunan Provincial Health and Health System carried out a special rectification work on “secondary bargaining” of drug consumption, requiring it to be completed in October. In ...
- Source: drugdu
- 77
- October 16, 2024
Yunnan Baiyao executive team adjustment

On October 11, Yunnan Baiyao issued the “Announcement on the Appointment of Senior Management Personnel”, appointing Li Shengli as its senior vice president. Li Shengli has held important positions in many pharmaceutical companies, including general manager, president, CEO, and chairman of Jiangsu Wanbang Pharmaceutical Marketing Biochemical Oncology Division, co-president, president, and chairman of Jiangsu Fosun Pharmaceutical Sales Co., Ltd., assistant to the president, vice president, senior vice president, executive president, and chief development officer of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. The joining of Li Shengli once again verified the change in Yunnan Baiyao’s talent training model, from internal talent training to the “internal training + external introduction” dual-channel talent model, to create a high-quality talent team that meets its future development needs. Pharmaceutical companies have established their own talent training and selection system, and the company and employees understand each other, have high loyalty, and there is almost no ...
- Source: drugdu
- 62
- October 16, 2024
“Sniper War” of Star Targets of Lung Cancer

Recently, Ascentage Pharmaceuticals’ APG-2449 has obtained CDE approval and will conduct two registered Phase III clinical studies for the treatment of non-small cell lung cancer. APG-2449 is a small molecule FAK inhibitor independently developed by Ascentage Pharmaceuticals with oral activity. It is a third-generation ALK/ROS1 TKI and the first FAK inhibitor in China to be approved by CDE for clinical trials. This may mean that the node for domestic drugs to disrupt the ALK target pattern is getting closer and closer, and it also indicates that the next blockbuster product of China’s innovative drugs is on the way. The saying “He who gets lung cancer gets the world” is widely circulated in the field of tumors. Lung cancer is the leading cause of morbidity and mortality of malignant tumors in China. The large number of lung cancer patients has always been a must-fight place for pharmaceutical companies. This is also ...
- Source: drugdu
- 50
- October 16, 2024
Africa Health

Organiser：Informa Markets Time：October 22 – 24, 2024 Address：19 Richards Drive Johannesburg Gauteng Midrand 1685 South Africa Exhibition hall：Gallagher Convention Centre Product range: Medical Devices: Laboratory equipment and configurations, emergency and transportation facilities, surgical equipment, nursing and monitoring equipment, etc. Medical Technologies: Orthopedic and rehabilitation technologies, medical building facilities and technologies, medical information and communication technologies, etc. Pharmaceuticals: Various types of finished pharmaceuticals, medicinal products, medical excipients, etc. Hospital Supplies: Disposable medical supplies, medical disinfectants, etc. Medical Supplies: Medical clothing and laundry technologies, nutritional meal preparation equipment, medical furniture, etc. About Africa Health： The Africa Health Exhibition in Johannesburg, South Africa, is the most significant healthcare event on the African continent. For many years, our mission and vision at Africa Health, aligned with the African Health Organization, have been to bridge the gap in healthcare business, knowledge, and skill development through meaningful connections, bringing the future of healthcare to ...
- Source: drugdu
- 94
- October 15, 2024
GCGR agonist rejected twice

Original Time Biopharmaceutical Editor October 14, 2024 09:20 Shanghai The weight loss drug concept stock Zealand has suffered another setback, as its new drug Dasiglucagon, which was launched to treat congenital hyperinsulinemia (CHI) in children, has once again been rejected by the FDA. Last December, Dasiglucagon was rejected by the FDA for the first time due to the discovery of defects in a third-party contract manufacturing factory. Zealand pointed out that the main reason for Dasiglucagon’s second rejection was that the FDA failed to complete the re inspection of third-party production factories, resulting in the approval process being put on hold. The FDA did not raise any concerns about the effectiveness or safety of Dasiglucagon. Dasiglucagon is a glucagon receptor (GCGR) agonist that acts to release stored glycogen from the liver into the bloodstream. Hypoglycemia is one of the most common acute complications of diabetes, and patients who have the ...
- Source: drugdu
- 62
- October 15, 2024
Victory! FDA approves Pfizer’s hemophilia A or B monoclonal antibody drug Marstacimab

Pfizer – after starting a showdown with a radical investor, being betrayed by two former executives, reuniting with two former executives, and ending work on an RSV drug – finally has some good news, straightforward. On Friday, the FDA approved Pfizer’s hemophilia A or B drug Marstacimab, which will be sold under the Hympavzi brand. This therapy is an anti tissue factor pathway inhibitor that helps hemophilia patients form blood clots to limit their bleeding episodes. A Pfizer spokesperson stated in an email to Endpoint News that the wholesale procurement cost for this weekly drug is $795600 per year, which is consistent with the WAC pricing for available prophylactic treatments for hemophilia A or B. It plans to start selling this drug this quarter. This drug is packaged as a pre filled automatic injection pen, which analysts say can help it find a place in the market. Given the maturity ...
- Source: drugdu
- 76
- October 15, 2024
FDA Approves Pfizer’s Hemophilia A or B Monoclonal Antibody Drug Marstacimab

On Friday, the FDA approved Pfizer’s hemophilia A or B drug Marstacimab, which will be sold under the Hympavzi brand. This therapy is an anti tissue factor pathway inhibitor that helps hemophilia patients form blood clots to limit their bleeding episodes. A Pfizer spokesperson stated in an email to Endpoint News that the wholesale procurement cost for this weekly drug is $795600 per year, which is consistent with the WAC pricing for available prophylactic treatments for hemophilia A or B. It plans to start selling this drug this quarter. This drug is packaged as a pre filled automatic injection pen, which analysts say can help it find a place in the market. Given the maturity of factor replacement and the moderate improvement of Mastacrolizumab compared to conventional prevention, Pfizer will have to rely to some extent on the argument of convenience to gain traction, “TD Cowen analyst wrote in a ...
- Source: drugdu
- 62
- October 15, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.